 |
|
Home | Piper Jaffray Reiterates Overweight Rating for Vanda Pharmaceuticals (VNDA) |
 |
Piper Jaffray Reiterates Overweight Rating for Vanda Pharmaceuticals (VNDA)
|
 |
- February 23, 2015
-
Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Jaffray in a report issued on Sunday. They currently have a $18.00 target price on the stock. Piper Jaffray’s target price would indicate a potential upside of 57.48% from the company’s current price. The analysts wrote, “VNDA reported a soft 4Q […]This article (Piper Jaffray Reiterates Overweight Rating for Vanda Pharmaceuticals (VNDA)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2015/02/22/piper-jaffray-reiterates-overweight-rating-for-vanda-pharmaceuticals-vnda/
|
 |
|
 |
|
 |
